Ratings Mithra Pharmaceuticals S.A.

Equities

MITRA

BE0974283153

Market Closed - Euronext Bruxelles Other stock markets 11:35:26 2024-04-24 am EDT			5-day change	1st Jan Change
0.2215 ^EUR	-2.42%		+0.45%	-82.34%

Apr. 22	Mithra Pharmaceuticals Obtains Court Protection Measures	MT
Mar. 08	Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MITHRA PHARMACEUTICALS S.A.	-82.34%	16.36M	C+
CSL LIMITED	-2.86%	87.31B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B	A-
BIOGEN INC.	-21.94%	29.36B	B-
UCB	+53.11%	24.49B	A
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.31B	C
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B	B
INCYTE CORPORATION	-17.60%	11.62B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B	D+
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	8.31B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes